ORIC ▼ -0.1% - ORIC Pharmaceuticals, Inc. $ORIC - ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial 23-OCT-2026 03:15 AM ET